Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination

Anticancer Research

Volumn 31, Issue 7, 2011, Pages 2447-2452

  Ohno, Satoshi ^a,b,c   Takano, Fumihide ^c   Ohta, Yasuyuki ^c   Kyo, Satoru ^c   Myojo, Subaru ^c   Dohi, Satoshi ^c   Sugiyama, Haruo ^d   Ohta, Tomihisa ^c   Inoue, Masaki ^c  

^a WASEDA UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Cancer vaccine; Immunotherapy; Myeloid dendritic cell; Wilms' tumor 1 (WT1)

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD33 ANTIGEN; LEUKOCYTE ANTIGEN; WT1 PROTEIN;

ARTICLE; FLOW CYTOMETRY; MYELOID DENDRITIC CELL; NEPHROBLASTOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; BLOOD CELL COUNT; CANCER VACCINES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GENITAL NEOPLASMS, FEMALE; HLA-A ANTIGENS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOLOGIC SURVEILLANCE; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRADERMAL; MIDDLE AGED; PEPTIDE FRAGMENTS; TREATMENT OUTCOME; TUMOR BURDEN; VACCINES, SUBUNIT; WT1 PROTEINS;

EID: 79961189927     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Oka Y, Tsuboi A, Elisseeva OA, Udaka K and Sugiyama H: WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets 2: 45-54, 2002. (Pubitemid 34627378)
2. Oka Y, Tsuboi A, Oji Y, Kawase I and Sugiyama H: WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20: 211-220, 2008.
3. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones C and Housman DE: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60: 509-520, 1990.
4. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH and Bruns GA: Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343: 774-778, 1990.
5. Sugiyama H: Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 73: 177-187, 2001.
6. Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K, Kawase I, Oji Y and Sugiyama H: Development of WTl peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem 13: 2345-2352, 2006. (Pubitemid 44184641)
7. Yang L, Han Y, Suarez Saiz F and Minden MD: A tumor suppressor and oncogene: the WT1 story. Leukemia 21: 868-876, 2007. (Pubitemid 46672061)
8. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H and Aozasa K: Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19: 804-814, 2006. (Pubitemid 43780450)
9. Ohno S, Dohi S, Ohno Y, Kyo S, Sugiyama H, Suzuki N and Inoue M: Immunohistochemical detection of WT1 protein in endometrial cancer. Anticancer Res 29: 1691-1696, 2009.
10. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I and Sugiyama H: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101: 13885-13890, 2004. (Pubitemid 39298502)
11. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H and Sakamoto J: A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 36: 231-236, 2006.
12. Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, Kawakami M, Nakajima H, Nishida S, Shirakata T, Oka Y, Shuin T and Sugiyama H: WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51: 519-530, 2007. (Pubitemid 46799719)
13. Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S, Hosen N, Ogata A, Kito K, Fujiki F, Nishida S, Shirakata T, Ohno S, Yasukawa M, Oji Y, Kawakami M, Morita S, Sakamoto J, Udaka K, Kawase I and Sugiyama H: Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol 56: 414-417, 2007.
14. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H and Yoshimine T: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108: 963-971, 2008. (Pubitemid 351656845)
15. Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimura T, Oka Y, Tsuboi A, Sugiyama H and Inoue M: Wilms' tumor 1 (WT1) peptide immunotherapy for gynaOecological malignancy. Anticancer Res 29: 4779-4784, 2009.
16. + T Cell memory in tumor immunology and immunotherapy. Immunol Rev 211: 214-224, 2006.
17. Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Tanaka-Harada Y, Hosen N, Nishida S, Shirakata T, Nakajima H, Tatsumi N, Hashimoto N, Taguchi T, Ueda S, Nonomura N, Takeda Y, Ito T, Myoui A, Izumoto S, Maruno M, Yoshimine T, Noguchi S, Okuyama A, Kawase I, Oji Y and Sugiyama H: A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. Anticancer Res 30: 2247-2254, 2010.
18. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J and Sparwasser T: Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 70: 7788-7799, 2010.
19. Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I and Sugiyama H: Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 51: 614-620, 2002. (Pubitemid 35440514)
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
21. Mami NB, Mohty M, Chambost H, Gaugler B and Olive D: Blood dendritic cells in patients with acute lymphoblastic leukaemia. Br J Haematol 126: 77-80, 2004. (Pubitemid 38859485)
22. +/CD38-primitive haematopoietic progenitors. Br J Haematol 119: 115-118, 2002.
23. Yanagimoto H, Takai S, Satoi S, Toyokawa H, Takahashi K, Terakawa N, Kwon AH and Kamiyama Y: Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol 114: 52-60, 2005. (Pubitemid 39642790)
24. Lissoni P, Vigore L, Ferranti R, Bukovec R, Meregalli S, Mandala M, Barni S, Tancini G, Fumagalli L and Giani L: Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. J Biol Regul Homeost Agents 13: 216-219, 1999.
25. Letsch A, Knoedler M, Na IK, Kern F, Asemissen AM, Keilholz U, Loesch M, Thiel E, Volk HD and Scheibenbogen C: CMV-specific central memory T cells reside in bone marrow. Eur J Immunol 37: 3063-3068, 2007. (Pubitemid 350131286)
26. Cavanagh LL, Bonasio R, Mazo IB, Halin C, Cheng G, van der Velden AW, Cariappa A, Chase C, Russell P, Starnbach MN, Koni PA, Pillai S, Weninger W and von Andrian UH: Activation of bone marrow-resident memory T-cells by circulating, antigen-bearing dendritic cells. Nat Immunol 6: 1029-1037, 2005. (Pubitemid 41486188)
27. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, Hämmerling GJ, Kyewski B, Hamann A, Umansky V and Schirrmacher V: Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 9: 1151-1157, 2003. (Pubitemid 37173699)
28. Di Rosa F and Pabst R: The bone marrow: a nest for migratory memory T-cells. Trends Immunol 26: 360-366, 2005. (Pubitemid 40835841)
29. Bonasio R and von Andrian UH: Generation, migration and function of circulating dendritic cells. Curr Opin Immunol 18: 503-511, 2006. (Pubitemid 43947581)
30. Inui A: Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52: 72-91, 2002.
31. Nakajima H, Kawasaki K, Oka Y, Tsuboi A, Kawakami M, Ikegame K, Hoshida Y, Fujiki F, Nakano A, Masuda T, Wu F, Taniguchi Y, Yoshihara S, Elisseeva OA, Oji Y, Ogawa H, Azuma I, Kawase I, Aozasa K and Sugiyama H: WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 53: 617-624, 2004. (Pubitemid 38858335)
32. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA and Ioannides CG: Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8: 3407-3418, 2002. (Pubitemid 35340715)
33. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M and Engelhard VH: Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21: 4016-4026, 2003. (Pubitemid 46606217)
34. + T-cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115: 739-746, 2005. (Pubitemid 40322250)
35. Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D'Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F and Rivoltini L: Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T-cells and monocyte/dendritic cell precursors. Cancer Res 66: 4943-4951, 2006.
36. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH and White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998. (Pubitemid 28144091)